Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity 2024-11-20 22:00
Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer 2024-05-23 20:42
Laekna Releases 2023 ESG Report 2024-04-29 20:30
Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024 2024-04-08 08:30
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024 2024-01-04 12:40
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results 2023-12-11 18:55
Laekna, Inc. (2105.HK) Announces Interim Results 2023 2023-08-25 08:00
1